Menu
Enrolling by invitation NCT05656664

Mitigation Efforts in Arsenic Exposure With Folic Acid Supplementation

No phase Interventional Arsenic and/or Arsenic Compound Adverse Reaction

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Folic Acid, Placebo.
Who it may be relevant to
Registry conditions: Arsenic and/or Arsenic Compound Adverse Reaction. Basic parameters: 18 years — 89 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Mitigation Efforts in Arsenic Exposure With Folic Acid Supplementation: Reducing Toxicity and Exploring the Impact on Lung Health

Overview

The purpose of this study is to evaluate the effects on folic acid supplementation in a population living in an environment with chronic arsenic exposure in Birmingham, Alabama.

Detailed description

Folic acid supplementation effects urinary arsenic excretion. In this project investigators propose to investigate if oral folic acid dietary supplementation can increase urinary arsenic metabolite excretion

Interventions

  • Dietary supplement Folic Acid
    Folic acid supplementation to assess for increased arsenic metabolite excretion
  • Other Placebo
    Placebo group to assess arsenic metabolite excretion

Primary outcome measures

  • Measurement of urine and blood arsenic metabolites [Time frame: 12 weeks]
Secondary outcome measures (2)
  • Respiratory Symptom Questionnaire [Time frame: 12 weeks]
  • Pooled Cohort Probability Score [Time frame: 12 weeks]

Eligibility criteria

Inclusion criteria

  • ≥18 years of age
  • Resident of the superfund site
  • Clinically stable with no significant changes in general health status in the past 4 weeks prior to screening as assessed by the investigator
  • Provide written informed consent

Exclusion criteria

  • Pregnancy
  • Ongoing folic acid nutritional supplementation
  • Methotrexate use
  • Megaloblastic anemia
  • Alcoholic liver disease
  • Malabsorptive syndromes - celiac disease, inflammatory bowel disease

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Prevention

Study locations

United States · 1 center
  • UAB Lung Health Center — Birmingham

Publications

  • Bozack AK, Hall MN, Liu X, Ilievski V, Lomax-Luu AM, Parvez F, Siddique AB, Shahriar H, Uddin MN, Islam T, Graziano JH, Gamble MV. Folic acid supplementation enhances arsenic methylation: results from a folic acid and creatine supplementation randomized controlled trial in Bangladesh. Am J Clin Nutr. 2019 Feb 1;109(2):380-391. doi: 10.1093/ajcn/nqy148. PMID 30590411

Identifiers

NCT: NCT05656664 · 300010144

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗